Pneumocystis jirovecii nucleic acids and associated biosynthetic pathways (P. jirovecii nucleic acid pathways)

Pneumocystis jirovecii is a host-specific fungal pathogen that causes Pneumocystis pneumonia (PCP), a severe infection primarily affecting immunocompromised individuals such as those with HIV/AIDS or transplant recipients (StatPearls, PMID: 31194443). The nucleic acids and associated biosynthetic pathways of P. jirovecii are essential for its growth and replication, serving as the primary targets for current clinical interventions. The most common therapeutic strategy involves the inhibition of the folic acid synthesis pathway; sulfamethoxazole inhibits dihydropteroate synthase (DHPS), while trimethoprim inhibits dihydrofolate reductase (DHFR), collectively preventing the production of tetrahydrofolate required for DNA and RNA synthesis (PubMed, PMID: 11733854). Other agents like pentamidine are thought to bind to the minor groove of fungal DNA, interfering with replication and transcription processes (PubMed, PMID: 8121511). Atovaquone targets the mitochondrial electron transport chain, which is coupled to the de novo synthesis of pyrimidines, further starving the organism of nucleic acid precursors (PubMed, PMID: 15546519). Monitoring mutations within these biosynthetic genes is increasingly important as they correlate with clinical treatment failures and drug resistance (CDC, 2023).

Other names

Pneumocystis jirovecii folic acid synthesis pathwayPneumocystis jirovecii DNA and RNA synthesisPneumocystis jirovecii pyrimidine biosynthesisP. jirovecii metabolic pathways

Inhibition of dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) to disrupt folate synthesis; interference with DNA binding and topoisomerase activity; inhibition of mitochondrial electron transport (cytochrome bc1 complex) to disrupt pyrimidine synthesis.